ArticleCurrent medicinal chemistry2026
Exploring the Functional and Prognostic Significance of miR-217 in Uterine Corpus Endometrial Carcinoma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe presence of microRNA-217 (miR-217) has been observed across various malignancies. However, its specific contribution to uterine corpus endometrial carcinoma (UCEC) is yet to be fully understood.
objectiveWe aimed to explore the role of miR-217 in UCEC.
methodsClinical and genomic data, alongside prognostic insights, for UCEC patients were sourced from the TCGA repository. A suite of statistical tools, including the Kruskal-Wallis test, Wilcoxon sign-rank test, and logistic regression, was deployed to scrutinize the correlation between miR-217 levels and clinical profiles. The Kaplan-Meier method was applied to chart survival curves, thereby assessing the prognostic implications of miR-217 levels and its target genes in UCEC. TargetScan, PicTar, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted to uncover the functional envelope of miR-217 target genes. An immune infiltration analysis provided further context to the role of miR-217 in immune modulation. We validated the expression of miR-217 in cell lines.
resultsmiR-217 demonstrates atypical expression across a spectrum of cancers, including UCEC. The expression of miR-217 in the Mixed&Serous subtypes of UCEC is significantly higher than that in the Endometrioid subtype (p = 0.008). The presence of miR-217 is associated with adverse impacts on overall survival (OS) and disease-specific survival (DSS) in UCEC patients, with hazard ratios (HR) of 1.55 (95% CI: 1.00-2.38, p = 0.048) and 2.05 (95% CI: 1.19-3.53, p = 0.010), indicating statistical significance. The prognostic significance of miR-217 in UCEC is highlighted by its status as a standalone indicator of patient outcomes. Diminished expression of genes targeted by miR-217, such as BCL2, DYRK1A, IGF1R, NDN, and NHS, is correlated with diminished OS in UCEC. miR-217 is intricately involved in the pathogenesis of UCEC, potentially through involvement in pathways like the AMPK signaling and FoxO signaling pathways. The expression of miR-217 in UCEC is significantly correlated with the infiltration level of some immune cells. Notably, in cell lines derived from UCEC, miR-217 expression is markedly increased.
conclusionThe up-regulation of miR-217 is strongly linked to an adverse prognosis in UCEC patients, suggesting its potential as a prognostic biomarker and a predictor of immunotherapy response in UCEC patients.
Indexed as
Identifiers
40304329What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.